395 related articles for article (PubMed ID: 33909239)
1. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
[No Abstract] [Full Text] [Related]
2. Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.
Martin P; Clarke C
EBioMedicine; 2021 Sep; 71():103567. PubMed ID: 34454401
[No Abstract] [Full Text] [Related]
3. Neutralizing SARS-CoV-2.
Poeschla E
Elife; 2020 Dec; 9():. PubMed ID: 33320086
[TBL] [Abstract][Full Text] [Related]
4. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
Chen Y; Shen H; Huang R; Tong X; Wu C
Lancet Infect Dis; 2021 Aug; 21(8):1071-1072. PubMed ID: 34051887
[No Abstract] [Full Text] [Related]
5. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
6. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Volkan E
Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
[TBL] [Abstract][Full Text] [Related]
8. What the Omicron wave is revealing about human immunity.
Willyard C
Nature; 2022 Feb; 602(7895):22-25. PubMed ID: 35110764
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
[No Abstract] [Full Text] [Related]
10. Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies.
Xie X; Han JB; Ma G; Feng XL; Li X; Zou QC; Deng ZH; Zeng J
Zool Res; 2021 Nov; 42(6):789-791. PubMed ID: 34704423
[No Abstract] [Full Text] [Related]
11. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
12. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
Wang GL; Wang ZY; Duan LJ; Meng QC; Jiang MD; Cao J; Yao L; Zhu KL; Cao WC; Ma MJ
N Engl J Med; 2021 Jun; 384(24):2354-2356. PubMed ID: 33822491
[No Abstract] [Full Text] [Related]
14. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
N Engl J Med; 2021 Jun; 384(22):2161-2163. PubMed ID: 33826816
[No Abstract] [Full Text] [Related]
15. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
16. Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants.
Fan S; Xiao K; Li D; Zhao H; Zhang J; Yu L; Chang P; Zhu S; Xu X; Liao Y; Ji T; Jiang G; Yan D; Zeng F; Duan S; Xia B; Wang L; Yang F; He Z; Song Y; Cui P; Li X; Zhang Y; Zheng B; Zhang Y; Xu W; Li Q
Emerg Microbes Infect; 2022 Dec; 11(1):212-226. PubMed ID: 34931939
[TBL] [Abstract][Full Text] [Related]
17. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
Sun S; He L; Zhao Z; Gu H; Fang X; Wang T; Yang X; Chen S; Deng Y; Li J; Zhao J; Li L; Li X; He P; Li G; Li H; Zhao Y; Gao C; Lang X; Wang X; Fei G; Li Y; Geng S; Gao Y; Wei W; Hu Z; Han G; Sun Y
Cell Mol Immunol; 2021 Apr; 18(4):1070-1073. PubMed ID: 33731916
[No Abstract] [Full Text] [Related]
18. A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination.
Murphy WJ; Longo DL
N Engl J Med; 2022 Jan; 386(4):394-396. PubMed ID: 34818473
[No Abstract] [Full Text] [Related]
19. The emerging plasticity of SARS-CoV-2.
McCormick KD; Jacobs JL; Mellors JW
Science; 2021 Mar; 371(6536):1306-1308. PubMed ID: 33766871
[No Abstract] [Full Text] [Related]
20. How 'killer' T cells could boost COVID immunity in face of new variants.
Ledford H
Nature; 2021 Feb; 590(7846):374-375. PubMed ID: 33580217
[No Abstract] [Full Text] [Related]
[Next] [New Search]
